Cited by 213Blood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and ManagementPlatelet Disorders and Treatments

Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects

Bloemenkamp, Kitty W. M., Rosendaal, Frits R., Helmerhorst, Frans M., Vandenbroucke, Jan P.·2000·Archives of Internal Medicine

Abstract

BACKGROUND: Results of recent studies show that the risk for venous thrombosis is highest during initial oral contraceptive use. This suggests a subgroup of females who are at immediate risk of thrombosis when exposed to oral contraceptives. OBJECTIVE: To determine whether women with inherited clotting defects who use oral contraceptives develop venous thrombosis at an earlier stage than do those without inherited clotting defects. METHODS: Analysis of the data from the Leiden Thrombophilia Study, a population-based case-control study with data on duration of oral contraceptive use and recently detected genetic coagulation disorders. Patients had a first episode of objectively proven deep vein thrombosis. Patients and controls were considered thrombophilic when they had protein C deficiency, protein S deficiency, antithrombin deficiency, factor V Leiden mutation, or prothrombin 20210 A mutation. RESULTS: Risk of developing deep vein thrombosis was greatest in the first 6 months and the first year of oral contraceptive use. Compared with prolonged use, the risk of developing deep vein thrombosis was 3-fold higher in the first 6 months of use (95% confidence interval [CI], 0.6-14.8) and 2-fold higher in the first year of use (95% CI, 0.6-6.1). Patients who developed venous thrombosis in the early periods of use were more often thrombophilic. Among women with thrombophilia, the risk of developing deep vein thrombosis during the first 6 months of oral contraceptive use (compared with prolonged use) was increased 19-fold (95% CI, 1.9-175.7), and in the first year of use, it was increased 11-fold (95% CI, 2.1-57.3). CONCLUSIONS: Women with inherited clotting defects who use oral contraceptives develop venous thrombosis not only more often but also sooner than do those without inherited clotting defects. Venous thrombosis in the first period of oral contraceptive use might indicate the presence of an inherited clotting defect.

Integrity signals

Registry

Crossref · 10.1001/archinte.160.1.49

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The most common clinical presentation of estrogen-related thrombosis is venous thromboembolism of the deep veins of the legs or pulmonary vessels, usually within the first few months of use.

    “The most common clinical presentation of estrogen-related thrombosis is venous thromboembolism (VTE) of the deep veins of the legs or pulmonary vessels, usually within the first few months of use.”

    From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [101]

  • Data from the population-based case-control Leiden Thrombophilia Study showed that the risk of developing VTE was greatest in the first 6 months of CHC use.

    “Data from the population-based case-control Leiden Thrombophilia Study showed that the risk of developing VTE was greatest in the first 6 months of CHC use.”

    From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [101]

Cites

Flagged first, then by citations

1 of the 27 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Bloemenkamp, K. W. M., Rosendaal, F. R., Helmerhorst, F. M., & Vandenbroucke, J. P.
Affiliations
Leiden University Medical Center (NL)
Venue
Archives of Internal Medicine
Published
2000-01-10
Volume
160
Issue
1
Pages
49
ISSN
0003-9926 (ISSN-L)
OpenAlex
W2163417915
Cited by
213
References
27
Citations by year
2026: 1 · 2025: 4 · 2024: 9 · 2023: 2 · 2022: 6 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 10 · 2016: 8 · 2015: 6 · 2014: 5 · 2013: 6 · 2012: 5
FWCI
9.23
Type
journal article
Language
en
Open access
closed
Locations
  • Archives of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
venous thrombosis, deep vein thrombosis, oral contraceptives, thrombophilia, duration of contraceptive use, protein C deficiency, protein S deficiency, antithrombin deficiency, factor V Leiden, prothrombin G20210A
MeSH terms
Adolescent, Adult, Blood Coagulation Disorders, Contraceptives, Oral, Female, Humans, Middle Aged, Risk, Risk Factors, Time Factors, Case-Control Studies, Venous Thrombosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review